Report Information More information from: https://www.wiseguyreports.com/reports/2258213
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2017 Report / Search Code: WGR2258213
Price
Description:
1-user PDF : $ 2000.0
Publish Date: 12 September, 2017
Site PDF : $ 4000.0
Enterprise PDF : $ 6000.0
Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lassa Fever Pipeline Review, H2 2017, provides an overview of the Lassa Fever (Infectious Disease) pipeline landscape. Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lassa Fever - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Lassa Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Lassa Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Lassa Fever (Lassa Hemorrhagic Fever) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 10 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively. Lassa Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Lassa Fever (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Lassa Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Lassa Fever (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Lassa Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Lassa Fever (Infectious
Disease) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Lassa Fever (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Lassa Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Contents:
Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Lassa Fever (Lassa Hemorrhagic Fever) - Overview Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Lassa Fever (Lassa Hemorrhagic Fever) - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Lassa Fever (Lassa Hemorrhagic Fever) - Companies Involved in Therapeutics Development Arno Therapeutics Inc Celgene Corp Etubics Corp Fab'entech SA GeoVax Labs Inc Kineta Inc Profectus BioSciences Inc Theravectys SA Lassa Fever (Lassa Hemorrhagic Fever) - Drug Profiles AR-12 - Drug Profile Product Description Mechanism Of Action R&D Progress CC-11050 - Drug Profile Product Description Mechanism Of Action R&D Progress FBH-003 - Drug Profile Product Description Mechanism Of Action R&D Progress GEOLM-01 - Drug Profile Product Description Mechanism Of Action R&D Progress infectious disease vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress KIN-1400 - Drug Profile
Product Description Mechanism Of Action R&D Progress lassa fever vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress lassa fever vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress lassa fever vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress lassa fever vaccine - Drug Profile Product Description Mechanism Of Action R&D Progress LHF-535 - Drug Profile Product Description Mechanism Of Action R&D Progress ML-29 - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibodies for Lassa Fever - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules for Lassa Fever - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile Product Description Mechanism Of Action R&D Progress ST-193 - Drug Profile Product Description Mechanism Of Action R&D Progress Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects Lassa Fever (Lassa Hemorrhagic Fever) - Product Development Milestones Featured News & Press Releases Jul 24, 2017: GeoVax Joins with Scripps Research Institute and Institute of Human Virology at University of Maryland School of Medicine to Develop Lassa Fever Vaccine Jul 11, 2017: Tulane University awarded $12 million to create Lassa vaccine and treatment May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer List of Tables Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Arno Therapeutics Inc, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Celgene Corp, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Etubics Corp, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Fab'entech SA, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by GeoVax Labs Inc, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Kineta Inc, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Profectus BioSciences Inc, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Pipeline by Theravectys SA, H2 2017 Lassa Fever (Lassa Hemorrhagic Fever) - Dormant Projects, H2 2017 List of Figures Number of Products under Development for Lassa Fever (Lassa Hemorrhagic Fever), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products by Targets, H2 2017 Number of Products by Stage and Targets, H2 2017 Number of Products by Mechanism of Actions, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017
wiseguyreports.com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349